Key Takeaways from the Microbiome Competitive Landscape Report
Over 130+ companies and 180+ pipeline drugs in Microbiome Competitive landscape.
Leading Microbiome companies developing novel drug candidates to improve the Microbiome treatment landscape include Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health, Scioto Biosciences, Adiso Therapeutics, and many others.
Servatus Biopharmaceuticals
Promising PD-1 and PD-L1 Inhibitors pipeline therapies in various stages of development include RBX 2660, SER-109, Blautix, SER-301, and many others.
Microbiome Overview
Microbiome refers to the collection of microbes and their interaction with the human body. The microbiome plays an important role in human physiology and disease. The microbes and their interaction with the human body show the various aspects of human biology. The human body possesses a number of different species particularly bacteria and fungi which help in digesting food, preventing infections, and performing numerous life-supporting tasks. Microbes can also be harmful to their human hosts. Role of Microbiota in Health and Disease in Metabolic Disorders.
Microbiome Pipeline Therapies and Key Companies
Ferring pharmaceuticals: RBX 2660
Seres Therapeutics: SER-109
4D Pharma: Blautix
And many others
Scope of the PD-1 and PD-L1 Inhibitors Pipeline Report
Coverage: Global
Key Microbiome Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
Key Microbime Pipeline Therapies: KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 , CTP-543, PF-06651600 and others.
Find out more about the PD-1 and PD-L1 Inhibitors treatment options in development @ Microbiome Clinical Trials
Table of Contents
Introduction
Executive Summary
Microbiome: Overview
Mechanism of Action
Application
Limitation
Approved Therapies
Microbiome: In-depth Commercial Assessment
Microbiome Collaboration Analysis by Companies
Competitive Landscape
Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Microbiome: Company and Product Profiles (Marketed Therapies)
JW Therapeutics
Company Overview
Relmacabtagene autoleucel
Product Description
Research and Development Activities
Product Developmental Activities
Microbiome: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Registered)
Comparative Analysis
CARsgen
Zevorcabtagene autoleucel
Mid-Stage Products (Phase II)
Cartesian Therapeutics
Descartes 011
Early Stage Products (Phase I)
Autolus Therapeutics
AUTO-8
Preclinical and Discovery Stage Products
Sana Biotechnology
SG299
Inactive Products
Microbiome – Unmet needs
Microbiome – Market drivers and barriers
Appendix
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services